(Q33370720)

26 July 2017

Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Hutcha Sriplung

2

0 references

Alan Geater

object named as

Alan Geater

Virasakdi Chongsuvivatwong

3

0 references

4

object named as

Virasakdi Chongsuvivatwong

1 reference

26 July 2017

Jing You

1

1 reference

26 July 2017

Lin Zhuang

5

1 reference

26 July 2017

Yun-Li Li

6

1 reference

26 July 2017

Hua Lei

7

1 reference

26 July 2017

Jun Liu

8

1 reference

26 July 2017

Hong-Ying Chen

9

1 reference

26 July 2017

Bao-Zhang Tang

10

1 reference

26 July 2017

Jun-Hua Huang

11

1 reference

26 July 2017

22 September 2008

1 reference

26 July 2017

BMC Infectious Diseases

1 reference

26 July 2017

8

1 reference

26 July 2017

123

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2334-8-123

26 July 2017

0 references

cites work

Customizing the management of chronic hepatitis B virus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

New and emerging treatment of chronic hepatitis B.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Antiviral therapy and resistance with hepatitis B virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

The immune response during hepatitis B virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

A review of entecavir in the treatment of chronic hepatitis B infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Pathogenesis of hepatitis B virus infection.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Cellular immune responses to the hepatitis B virus polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-123

Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2570678

Recurrent hepatitis B, hepatitis C, and combined hepatitis B and C in liver allografts: a comparative pathological study

31 October 2018

1 reference

12 December 2020

Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection

1 reference

12 December 2020

A new hypothesis of pathogenetic mechanism of viral hepatitis B and C

1 reference

12 December 2020

Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2334-8-123

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference